Pomegranate Health Review

Our assessment

Pomegranate Health does what this whole category avoids: it tells you which pharmacy will fill your prescription, by name, before you buy. Its ordering screen lists six dispensers with their current stock state, and quotes the regulation behind a one-vial dispensing limit. Against that, the advertised figure is a floor. It sits above plan-length and tier selectors whose other combinations carry no published price, and the one brand-name product on the screen shows a copay, not a cash price — a number that only means something if you already have coverage this seller doesn't provide.

Six pharmacies, named, with their stock state

Ninety-four of the four hundred and twenty sellers here name a pharmacy at all. Most of the rest describe a category — licensed, FDA-registered, 503A — and stop. Pomegranate publishes a list under each drug on its ordering screen, and the list isn't decorative: one entry is marked sold out, which is live inventory rather than marketing.

It goes further. Beside one dispenser sits a notice explaining that under a named regulation on compounded sterile preparations and beyond-use dating, that pharmacy may only dispense a single vial per order. That is a supply constraint quoted from the rule that causes it, published before checkout.

A named pharmacy is one you can look up in a state board register. A pharmacy with its stock state attached is one you can plan around.

The advertised figure is a floor under a matrix

The product page says the price starts at a figure. That word is doing work. On the ordering app the same drug appears above two selectors, a plan length running from one month to six and a tier labeled starter or advanced, and only that one number is printed.

So the published figure describes one cell of a grid, and the other cells carry no price anywhere on the site. That isn't a hidden fee. It's an unpublished plan, and you find out what your combination costs after you commit to it.

The tirzepatide lane behaves the same way. Both products are sold as combination preparations, the semaglutide with a B vitamin and the tirzepatide with a form of B3. A combination preparation isn't the same product as the plain drug, so these figures don't line up against a single-ingredient preparation elsewhere.

The brand-name product has no cash price

Three items on the ordering screen — an oral brand-name GLP-1, a combination weight medication and metformin — are each priced as a copay, described as being as low as nothing. That is not a cash rate. It assumes a plan that is already paying, and this seller doesn't sell coverage.

Nine of the four hundred and twenty sellers here carry a figure that holds only once coverage is in place, and this is one of them. If you're paying yourself, treat that zero as no price at all.

It's still worth knowing the lane exists. An FDA-approved oral GLP-1 on the same screen as two compounded preparations tells you the operator can route a prescription either way. It just won't tell you what the approved one costs out of pocket.

What it says about itself, and what it doesn't

The operating company is named in the first person in the HIPAA privacy policy, which is a real disclosure. No individual clinician is named anywhere. Three hundred of the four hundred and twenty sellers here name nobody who prescribes.

The absence of a membership fee is stated three separate ways on the priced page: the header strip says no membership requirements and no hidden fees, the card says no additional fees or membership costs, and the FAQ answers the insurance question by saying one clear price covers care, medication and shipping. One hundred and twenty-nine of the four hundred and twenty sellers here charge no membership.

There is no state list. Two hundred and eighty-six of the four hundred and twenty sellers here publish no service area at all, so the silence is ordinary. What isn't ordinary is that the only geography on the site is a published surcharge for shipping to Alaska, Puerto Rico and Hawaii, which implies those are served and says nothing about anywhere else.

One line on the product page sits awkwardly beside the rest. It says the medication comes direct from an FDA-licensed manufacturer. Two paragraphs down, the same page states, correctly, that compounded formulations are not reviewed or approved by the FDA. Both sentences are on one screen.